Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer

被引:3
作者
Oyama, Baku [1 ]
Morikawa, Kei [1 ]
Sakaguchi, Tadashi [2 ]
Tsunoda, Akihito [1 ]
Kida, Hirotaka [1 ]
Inoue, Takeo [1 ]
Mineshita, Masamichi [1 ]
机构
[1] St Marianna Univ, Sch Med, Dept Resp Med, Kawasaki, Kanagawa, Japan
[2] Matuzaka City Hosp, Dept Resp Med, Matsusaka, Japan
关键词
afatinib; drug-induced hypersensitivity syndrome; HHV-6;
D O I
10.2169/internalmedicine.4237-19
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib treatment was discontinued on the same day. On Day 26, the patient displayed blepharedema and multiple irregular erythema covering her entire body. Drug-induced hypersensitivity syndrome (DIHS) was suspected, and the systemic administration of 30 mg/day prednisolone was administered. The symptoms subsided thereafter. A blood test analysis 3 weeks after onset revealed a reactivation of Human herpesvirus 6 (HHV-6) and a diagnosis of DIHS due to afatinib therapy was confirmed.
引用
收藏
页码:441 / 444
页数:4
相关论文
共 13 条
[1]   DRESS syndrome [J].
Descamps, Vincent ;
Ranger-Rogez, Sylvie .
JOINT BONE SPINE, 2014, 81 (01) :15-21
[2]  
Hashimoto K, 2006, J JAPANESE DERMATOLO, V116, P1575
[3]  
Higashi N, 2008, NIHON IKA DAIGAKU IG, V4, P205
[4]  
Kuschel Stephanie L, 2018, Pract Dermatol, V2018, P41
[5]  
Ros J, 2018, BMJ CASE REP, V2018
[6]  
Roujeau JC, 2009, DERMATOL SIN, V27, P203
[7]  
Salame N, 2019, J DRUGS DERMATOL, V18, P468
[8]  
Sequist LV, 2013, J CLIN ONCOL, V31
[9]   Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019 [J].
Shiohara, Tetsuo ;
Mizukawa, Yoshiko .
ALLERGOLOGY INTERNATIONAL, 2019, 68 (03) :301-308
[10]   Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome [J].
Suzuki, Y ;
Inagi, R ;
Aono, T ;
Yamanishi, K ;
Shiohara, T .
ARCHIVES OF DERMATOLOGY, 1998, 134 (09) :1108-1112